Mouse genomic representational oligonucleotide microarray analysis: detection of copy number variations in normal and tumor specimens by Lakshmi,  B. et al.
Mouse genomic representational oligonucleotide
microarray analysis: Detection of copy number
variations in normal and tumor specimens
B. Lakshmi*, Ira M. Hall*, Christopher Egan*, Joan Alexander†, Anthony Leotta*, John Healy‡, Lars Zender*,
Mona S. Spector*, Wen Xue*, Scott W. Lowe*, Michael Wigler*§, and Robert Lucito*§
*Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724; †606 Fairfax Avenue, Apartment A, Norfolk, VA 23507; and ‡Helicos BioSciences,
One Kendall Square, Building 200, Cambridge, MA 02139
Contributed by Michael Wigler, April 18, 2006
Genomic amplifications and deletions, the consequence of somatic
variation, are a hallmark of human cancer. Such variation has also
been observed between ‘‘normal’’ individuals, as well as in indi-
viduals with congenital disorders. Thus, copy number measure-
ment is likely to be an important tool for the analysis of genetic
variation, genetic disease, and cancer. We developed representa-
tional oligonucleotide microarray analysis, a high-resolution com-
parative genomic hybridization methodology, with this aim in
mind, and reported its use in the study of humans. Here we report
the development of a representational oligonucleotide microarray
analysis microarray for the genomic analysis of the mouse, an
important model system for many genetic diseases and cancer. This
microarray was designed based on the sequence assembly MM3,
and contains84,000 probes randomly distributed throughout the
mouse genome. We demonstrate the use of this array to identify
copy number changes in mouse cancers, as well to determine copy
number variation between inbred strains of mice. Because restric-
tion endonuclease digestion of genomic DNA is an integral com-
ponent of our method, differences due to polymorphisms at the
restriction enzyme cleavage sites are also observed between
strains, and these can be useful to follow the inheritance of loci
between crosses of different strains.
mouse genome  polymorphism  segmentation  CGH  probe selection
Copy number variation is increasingly being recognized asimportant to understanding pathophysiology and genetics in
humans. For example, in cancer, deletions are used tomap tumor
suppressors and amplifications to map oncogenes. Some genetic
diseases, both inherited and spontaneous, can be attributed to
mutations altering copy number. Moreover, wide variation in
copy number is present in the normal human population, and
although not yet proven, this variation is expected to alter normal
physiology.
Very large scale deletions and duplications can be observed
cytogenetically by chromosome banding and comparative
genomic hybridization (CGH) on chromosomes. More recently,
higher resolution has been achieved by array CGH, first per-
formed with BACs (1). With the advent of the completion of the
human genome sequence, methods with even higher resolution
are now available, all based on using oligonucleotide probes
mapped to the genome. These methods include whole genome
hybridization (2, 3) and representational approaches (4) that we
pioneered. High-density SNP arrays that use representational
technology (5) can also be used to detect copy number changes.
The success of representational oligonucleotide microarray
analysis (ROMA) depends in part on the simplification of the
genome that results from PCR amplification of genomic DNA,
restriction endonuclease cleavage, and adapting fragments by
ligation to primers (6). Algorithms based on the human genome
assembly (7) make possible the design of probes that hybridize
to representations. Fundamentally, ROMA depends on the
development of high-density oligonucleotide arrays, and in
particular on methodology that allowed for the flexible design
and rapid fabrication of arrays, enabling us to optimize probe
selection. Such technology is available from NimbleGen Sys-
tems, that allows up to 800,000 oligonucleotide features to be
fabricated by using mirror-directed laser photochemistry (8).
The NimbleGen fabrication system allows the rapid redesign of
an array, from assay to assay, at no extra cost.
Our initial design for a ROMA array was based on the human
genome sequence assembly. The array was designed with
84,000 probes, designed from short (200–1,200 bp) candidate
fragments based on BglII representations, and then further
empirically selected based on performance parameters we es-
tablished. We demonstrated its use in detecting amplifications
and deletions in cancers, the widespread variation of copy
number present in the human population, and de novomutations
found in some children with genetic disorders (4, 9). Here, we
describe the design and implementation of a ROMA array based
on BglII representations of the mouse genome sequence
assembly.
Mouse models have become increasingly important for the
study of human diseases, such as cancer and genetics. Many
cancer models revolve around the study and understanding of
one particular gene, but others are more global models, focused
on the recapitulation of cancer etiology and gene discovery.
Mouse models have also been widely used to understand the
known human disease genes (10) and to model known genetic
alterations (11), but also to discover genes that are involved in
pathophysiology, such as obesity (12) and diabetes (13). In these
efforts, particularly the latter, we see a role for measuring copy
number, both as a means for gene discovery, and as a method to
build appropriate models of human disease.
Both BAC and cDNA fragment arrays have already been used
to measure gene copy number in numerous mouse neoplasias
(14, 15). We have developed a mouse ROMA array because such
arrays are more available to us, but also because they are better
defined, more accurately reproduced, and can be of higher
resolution. Moreover, because representations are generated by
restriction endonuclease digestion, the ROMA is sensitive to
single nucleotide polymorphisms between strains, and this can be
used to advantage in certain circumstances.
We show the utility of these arrays in detecting changes in copy
number in cancers, and assessing differences between inbred
strains. The method for probe selection is provided online at our
web site (http:roma.cshl.org). Although the method for mak-
ing the mouse array follows closely the method we used for
making the human array, there is much greater genetic variation
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within the murine species than in Homo sapiens, and hence
application of ROMA to the laboratory mouse requires greater
care in experimental design.
Results
Representations. A representation is a sampling of the genome
that reduces complexity. This effectively increases signal to noise
during hybridization, because there is less ‘‘extraneous’’ labeled
genome contributing to nonspecific hybridization. In addition,
representations can be prepared from very small amounts of
DNA, i.e., very few cells, a common practice when working with
tumors, and some other biological samples. The disadvantage of
making representations is the extra step, one that must be
conducted with great care to achieve reproducibility. We gen-
erally use a two-color hybridization to compare a test sample to
a reference sample, each prepared in parallel to minimize
variation caused by representation. A representation is prepared
by digestion of the genome with a restriction endonuclease,
ligation of oligonucleotide adaptors and PCR amplification with
the same adaptors. Taq polymerase generally does not amplify
large fragments as efficiently as small fragments, resulting in the
preferential amplification of fragments in the size range of
200–1,200 base pairs, thereby reducing the complexity. The
degree of complexity reduction depends on the choice of re-
striction endonuclease. We have based the mouse array on
representations prepared by using the restriction endonuclease
BglII, the same enzyme we used for the human array. We
estimate complexity is reduced to 3% of the original genome.
Probe and Array Design. Probes were designed based on Build 30
(updated to Build 33) of the mouse genome sequence, which is
an assembly of reads predominantly fromC57BL6. The genome
was digested ‘‘in silico’’ with BglII (AGATCT), and 200,000
fragments (100–1,200 bp long) were culled. Multiple distinct and
minimally overlapping 50-bp oligonucleotide sequences, the
candidate probes, were generated for each fragment. Each
50-mer sequence was annotated for exact matches in the genome
by using a Burroughs–Wheeler transformation and algorithm as
described (7). Two critical counts were calculated for each
candidate probe, corresponding to the number of exact matches
of 21- and 15-bp substrings in the mouse genome. These are
measures of repetitiveness. Based on humans, we have identified
empirically acceptable counts for probes (7). Limits were set on
consecutive runs of single nucleotides, and GC content for
further probe selection. After taking these criteria into account,
up to four probes were picked per fragment. Up to 25 bp of
overlap between probes was allowed. A final set of 650,000
probes was chosen to be as unique as possible within the genome,
and satisfying the above conditions. The resulting probe set was
synthesized on our arrays with overlapping subsets so that the
resulting data could be normalized across arrays to more accu-
rately pick a final set of 84,000 probes.
Probe Selection. As described in ref. 4, the probes were validated
by using depletion experiments. A depletion experiment com-
pares a standard BglII representation to a BglII representation
that is depleted of a predictable subset of fragments. A depletion
representation is commonly prepared by digesting the represen-
tation just before its amplification with a second restriction
endonuclease. By doing so, all representational fragments con-
taining a cleavage site for the second restriction endonuclease
will not be amplified in the final representation, the equivalent
of being depleted from the representation. We then compare a
representation to a depleted representation. Assuming the
mouse genome is reliable we should be able to predict which
probes will have elevated ratios.
We do not perform a set of depletion studies that covers all
probes. Rather, we determined during the development of the
human ROMA array, and confirmed this for the mouse array,
that the probes with the highest ratio also had the highest
intensities in the nondepleted representation. For an example,
see Fig. 1A where the probe ratios are graphed as a function of
intensity in the (undepleted) representation channel. Probes
predicted to be depleted due to the presence of an internal
cleavage site are in red, and all others are in green. The depleted
probes have ratios correlated to the intensity. The intensity
measurements for all probes for all 650,000 probes from four
different hybridizations were measured, and as expected a
fraction, of the probes do not perform as well as the others. The
top 84,000 probes were picked based on intensity and a new
NimbleGen array designed and synthesized. Having optimized
for probe performance on the array, the final array design could
now be used to analyze biological samples such as tumor material
or DNAs from specific mouse strains.
Tumor Genomes. As an illustration of mouse ROMA, Fig. 2A
shows the analysis of a tumor obtained from a mouse model of
liver cancer (23). Hepatoblasts from a p53/ mouse were
transduced with a murine stem cell virus retrovirus coexpressing
the Myc oncogene, and transplanted into mice. The tumors were
excised from the liver and cultured, and DNA was prepared.
These samples were compared to a DNA sample from the parent
animal’s tail by ROMA.
It is clear that there is an amplicon in this tumor. The probe
data are annotated for probe genomic position so that it is easy
to obtain the chromosome location of any lesion observed. We
can zoom in on an amplicon that is found in the beginning of the
q arm of chromosome 9 (Fig. 2B). The genome coordinates of
the probes lying outside of the amplicon can be used as break
points to identify the gene content for the regions of interest by
using publicly available gene browsers such as the University of
California, Santa Cruz, Genome Browser (www.genome.ucsc.
edu). If we select the amplicon (coordinates chr9:6,896,942–
8,515,171, build 33) and identify the gene content, we can easily
determine that there are 15 full-length gene candidates within
this region. This region is seen amplified in several types of
cancer such as liver and ovarian cancer (23). These data were
used along with that from other samples mouse and human to
determine the most likely candidate genes. Gene candidate
Fig. 1. The distribution of measured probe ratios from a depletion experi-
ment as a function of intensity of the nondepleted representation channel, for
the 84,000 probes in the final selection. The y axis is the ratio measurements
and the x axis is the intensity, both plotted in log scale. Probes that derive from
fragments with an internal HindIII cleavage site are red, and those that derive
from fragments without an internal site are shown in blue.






validation was used to determine that the genes IAP1, IAP2, and
YAP1 within this region are amongst the likely target genes
important to the development and progression of cancer (see ref.
23 for a more detailed analysis of these gene candidates).
To make the identification of lesions, we use more automated
algorithms to perform what is commonly referred to as ‘‘seg-
mentation,’’ to partition the log ratios of the intensities into
segments of uniform distributions. The ratios are arranged in
genome order and are divided into blocks of 100 data points with
arbitrary boundaries. Then, the boundaries of the segments are
iteratively moved byminimizing the variance, and further refined
by using a two-distribution Kolmogorov–Smirnov null hypothesis
test (16). Only boundaries that give a P value statistic of 105
are accepted. This method is excellent for large lesions com-
prising of six or more probes. A Hidden Markov Model may
detect smaller lesions.
This technique has utility to identify copy number variations
in tumor samples from mouse models or human cancer. These
regions can be used to map cancer gene candidates, and this
information can be cross referenced to the human location based
on synteny. Using these methods, we have identified a gene that
is involved in human cancer, demonstrating the utility of iden-
tification of copy number fluctuations in mouse cancer models
to identify genes that are mutated in human cancer.
Strain Polymorphism and Implications for Analysis. ROMA per-
formed on two different humans reveals two major types of
polymorphisms (4, 9). SNPs are detected when the two individ-
uals differ at a BglII cleavage site that causes a restriction
fragment length polymorphism deleting a fragment in the rep-
resentation. Copy number polymorphisms (CNPs) are detected
as altered intensity ratios of clusters of nearby probes. In
humans, CNPs can be found as more than, or less than, the
expected copies per genome.
Much like human ROMA, the mouse ROMA chip will also
identify both of these types of polymorphisms, much more
striking between inbred laboratory strains than anything seen in
humans. Fig. 3B shows a comparison of BALBcByJ to
C57BL6J (hereafter referred to as BALBc and C57BL6). We
observe an exceedingly asymmetric distribution of differences,
with a large number of clustered single probe events, indicating
low hybridization from BALBc. This finding is in stark com-
parison to a self-to-self hybridization where the samples com-
pared were liver and tail from a C57BL6 mouse (Fig. 3A). This
difference is readily explainable as SNPs distinguishing the
strains. In the present case, the mouse array is designed from the
sequence assembled mainly from C57BL6, with the expectation
of BglII fragment lengths predicted from that strain. Moreover,
probes were selected by hybridization to DNA from that strain.
Interestingly, the SNPs between the two strains cluster into
regions as shown in Fig. 3D surrounded by genomic regions of
much higher similarity between the two strains.
This interpretation was confirmed by PCR analysis (Fig. 4).
PCR primers were designed 100–300 bp on either side of the
BglII cleavage sites of the expected representational fragment,
and genomic DNA from C57BL6 and BALBc were used as
template. The amplified fragments were digested with BglII. If
both BglII cleavage sites are present, the expected fragment
length will be obtained. If one of the BglII cleavage sites is
altered by the presence of a SNP, the digested fragment will be
larger. Three proposed SNPs were selected from a cluster and
tested by this method, and the expected results were obtained.
For each fragment, both BglII cleavage sites in C57BL6 were
retained, and one cleavage site in BALBc was lost. This analysis
shows that the isolated probes with large negative log ratios are
likely to reflect SNPs within BglII restriction sites, although in
theory such single probe differences could also occur as a result
of large internal insertions that alter the size of a BglII fragment,
significant alteration within the probe sequence itself, or small
deletions that encompass only a single probe.
Most of these polymorphisms, although not in adjacent
probes, are regionally clustered, indicating that different regions
of highly diverged ancestral genomes became fixed during in-
breeding, whereas much of the remaining genome between
C57BL6 and BALBc is nearly identical. Different strains show
different patterns of fixation (I.M.H., C.E., B.L., Srinath Srindar,
Deepa Pai, and M.W., unpublished data).
As expected, CNPs are also identified in the comparison of the
two strains. In Fig. 3C, a CNP was identified, where fewer copies
are present in BALBc. Therefore, this region is likely to be
present as two copies in BALBc as compared to four copies in
C57BL6 because these are inbred strains. Another CNP, shown
in Fig. 5A, was one of several CNPs detected with the lower limit
of probes for the segmentor to identify a lesion, and copy number
was validated by quantitative PCR. Three probes within the CNP
region were tested and normalized to the proximal sequences
flanking the CNP. The results show roughly half the copy
number for the probes within the CNP (Fig. 5B) in BALBc as
compared to C57BL6 (similar to the CNP discussed earlier).
Discussion
Measurement of gene copy number in humans is now widely
recognized as a valuable tool for the analysis of genetic variation
in cancer and genetic disease. The laboratory mouse is the
premier animal model for human disease, and we therefore
sought to develop a similar tool for mice. We used our experi-
ence with ROMA as a guide. The resulting genome array is built
on the same principles, and functions similarly to the human
version. The array can detect duplications, amplifications and
deletions in the mouse genome, with applications in mouse
Fig. 2. The genomic profile of a DNA sample derived from a tumor gener-
ated in a mouse model of liver cancer. Tumor representations were compared
to representations prepared from the parent DNA. (A) The profile of the entire
genome. The x axis is the genome order concatenating the entire genome
from chromosome 1 to chromosomes Y. The y axis is the ratio measurements
obtained, graphed in log scale. The blue dots connected by a blue line are the
normalized ratio measurements for each probe. The red line is the segmented
data for the same experiments. Deletions are in the downward direction, and
amplifications are in the upward direction. (B) Magnified view of a region on
chromosome 9 that is genomically amplified and contains the oncogene
candidates IAP1, IAP2, or YAP1.
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cancer models and to discriminating the genetic differences
between mouse strains. Experimental design and application in
mice must differ somewhat from humans because of the exis-
tence of inbred strains of mice, because there is greater genetic
variation in mouse than in humans, and because these genetic
differences are distributed in distinct clusters between strains.
We detect two types of genetic variation between mice, most
prominently between inbred strains. These are SNPs that result
in restriction fragment-length polymorphisms, which become
apparent because ROMA is based on restriction endonuclease
cleavage and CNPs (see Fig. 3). Both types of variation are highly
nonuniform, clustering in specific locations along the genome.
The variation within these regions is far greater than anything we
observe in humans, and more resembles differences we see
between humans and primates (data not shown). Between these
regions are regions with almost no variation, far less than we
observe between different individual humans. In this report, we
show a comparison of only two inbred strains of mice, BALBc
and C57BL6, but the phenomenon is present between any two
strains, with different regions of clustering. These types of
studies have been undertaken by others (17, 18) using arrays that
cannot detect SNPs. The extreme variation we observe is un-
doubtedly a consequence of the mosaic nature of the inbred
mouse genome, with different strains containing unique com-
binations of genomic segments derived from genetically diverged
subspecies (19). The marked differences between strains can be
exploited during genetic crosses of strains in the mapping of
complex traits, but the corollary is that, in tumor studies, one
must take great care to match genomes.
When we examine tumor genomes in humans, we are often
forced to compare a cancer from one patient to the normal DNA
of another individual. In humans, where there are few polymor-
phisms, we can still interpret our data by making a compendium
of the common and rare CNPs, and masking differences at these
sites. Between inbred strains of mice, because there are so many
differences dispersed through out the genomes, this would be an
extreme nuisance. However, in the controlled setting of the
laboratory, and without the need for institutional review board
approval, comparing a tumor to normal DNA from the tumor-
bearing animal is, fortunately, not an issue. It might seem that it
suffices to compare tumors to DNA from the same inbred strain,
but we have found that even this has perils. Inbred strains do
have genetic variation that we detect, so the comparison should
be between the tumor and the tumor-bearing animal whenever
possible. (This is all of the more imperative if the strain has been
out-crossed.) When the experiment is carefully designed, we can
clearly see genomic alterations that are tumor specific, as
demonstrated in Fig. 2. The alterations can be easily mapped to
the mouse genome to identify oncogene candidates and the
region can be compared to the syntenic region in the human
genome. In the particular case that we illustrate, this method was
used to find a strong candidate oncogene in mouse liver cancer
that is also amplified in the syntenic region in human cancer.
Fig. 3. The genomic profile comparison of differing mouse strains. (A) The entire genome profile of a comparison of one strain to itself. (B) The entire genome
profile of the mouse strain BALBc compared to C57BL6. (C) Magnified view of a region containing a CNP, with fewer copies in BALBc as compared to C57BL6.
(D) Magnified view of a region from the comparison of C57BL6 to BALBc, where there is a region dense with SNPs between the two strains. On all graphs, the
x axis is the genomic order as described above, and the y axis is the ratio measurements obtained, graphed in log scale. The red line is the segmented data.






We have used ROMA for measuring copy number, but there
are several other methods that have been used for measurements
with humans that can be adapted to the mouse. BAC arrays have
already been used in mice for this purpose (17). Our preference
for ROMA, aside from the obvious one of familiarity (to us), is
its f lexibility, reproducibility, and even cost. Our arrays, which
are manufactured by NimbleGen Systems, are made to our
design, and the arrays are reusable. In this report, we use arrays
with 84,000 probes, and this is sufficient for most applications,
but we have recently designed arrays with 390,000 probes for
humans, and these work well and give higher resolution. Because
of the density of restriction fragment-length polymorphisms in
mice, it would not be difficult to design a specialty ROMA array
for detecting strain heterogeneity at high resolution. Recently,
we have adapted the ROMA methodology to detect differences
in methylation patterns in two tissues, a method we call MOMA
(methylation detection representational oligonucleotide mi-
croarray analysis). MOMA should be especially valuable when
applied to mouse because any tissue from the same individual
animal is readily available. The probe selection procedures,
current probe coordinates, and protocols for our mouse ROMA
BglII array are available from the authors upon request.
Materials and Methods
Supplies. Cot-1 DNA (15279-011) and yeast tRNA (15401-029)
were supplied by Invitrogen. Restriction enzymes, ligase, and
Klenow fragments (M0212M) were supplied by New England
Biolabs. The Megaprime labeling kit, Cy3-conjugated dCTP,
and Cy5-conjugated dCTP were supplied by Amersham Phar-
macia. Taq polymerase was supplied by Eppendorf. Centricon
YM-30 filters were supplied by Amicon (42410), and formamide
was supplied by Amresco (0606-500). Phenol–chloroform was
supplied by Sigma (P2069).
Array Design.Oligonucleotide probes are designed in silico from
the mouse genome, build 30. The genome was digested in silico
by the restriction enzyme, and 200,000 fragments were
selected that are 100–1,200 bp long. For every fragment,
constituent 50-bp probes were annotated by using a genome
dictionary (7), a previously developed algorithm. We allowed
the probes to overlap by 25 bp. Annotation of each probe
includes the frequency of occurrence of consecutive 21-mer,
frequency of occurrence of consecutive 15-mer in the genome,
consecutive runs of single nucleotides, and its GC content. A
final set of 650,000 probes was chosen to be as unique as
possible within the genome. All probes that satisfied the
following criteria were selected for validation: frequency of
21-mer  2; runs of ATs  6; runs of CGs  4, and GC
percentage within 30–60% and 15-mer frequency as low as
possible to give us four probes per fragment. We tested all
650,000 probes, predicted to be complementary to short BglII
fragments, arrayed on four chips.
Representation. BglII representations, in general, were prepared
as described (20). A major change is that amplification was
carried out in an MJ Research Tetrad. Eight 250-l tubes were
used for amplification. The cycle conditions were 95°C for 1 min,
72°C for 3 min, for 20 cycles, followed by a 10-min extension at
72°C. Representations depleted of specific fragments by restric-
tion enzyme were prepared in the same manner with the
following modification. After ligation of adaptor, the mixture
was cleaned by phenol–chloroform extraction, precipitated, and
resuspended. The ligated fragments were split, half being di-
gested with the second enzyme (HindIII in this case) and the
other half mock digested. This material was then used as
template in the PCR as described above.
Labeling and Hybridization. Two DNAs for comparison were
labeled as described (21) using reagents from the Amersham
Pharmacia Megaprime labeling kit with 10 l of label (Cy3-
Fig. 5. Quantitative PCR validation of a CNP identified in the comparison of
the two mouse strains analyzed. (A) The probe ratio data for the CNP region
graphically represented and arrows identifying the probes whose sequences
were used to generate Q-PCR primers. The x axis is the genome order, and the
y axis is the probe ratio plotted in log scale. (B) The results of quantitative PCR
graphed as a histogram. The x axis is the three probes and the average of the
controls. The y axis is the calculated copy number in relation to the control
probes, being set to a value of 1.
Fig. 4. Validation by PCR of several probes containing possible SNPs iden-
tified from the comparison of C57BL6 to BALBc. Fragments were amplified
such that they were larger than the genomic BglII representational fragment
and digested with BglII to detect the presence of SNPs in one or both BglII
cleavage sites. C57BL6, fragment amplified from C57BL6; C57BL6-D, frag-
ment amplified from C57BL6 digested with BglII; BALBc, fragment amplified
from BALBc; and BALBc-D, fragment amplified from BALBc digested with
BglII. The arrows point to the fragment being queried. The ratio is plotted on
the y axis in log scale, and the x axis is a genome order. The markers on the gel
picture (M) are a 100-bp ladder.
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dCTP or Cy5-dCTP). In addition, each experiment was hy-
bridized in duplicate, where in one replicate, the Cy5 and Cy3
dyes were swapped (i.e., ‘‘color reversal’’). Hybridizations,
washing, and scanning were also performed as described (4,
21). Samples were denatured in anMJ Research Tetrad at 95°C
for 5 min and then incubated at 37°C for 30 min. Samples were
spun down and pipetted onto a slide prepared with lifter slip
and incubated in a hybridization oven such as the Boekel
InSlide Out oven set at 42°C for 14–16 h. Slides were washed
and then scanned immediately with an Axon GenePix 4000B
scanner. GENEPIX PRO 4.0 software was used for quantitation of
intensity for the arrays. Array data were imported into S-PLUS
for further analysis. Measured intensities without background
subtraction were used to calculate ratios. Data were normal-
ized by using an intensity-based lowess curve fitting algorithm
similar to that described in ref. 22. Data obtained from
color-reversal experiments were averaged and displayed as
presented in the figures
Quantitative PCR. Three BglII fragments (A, B, C) were chosen
for verification. For each fragment, primers were designed to be
in the 75- to 150-bp range. For each primer pair, a group of three
reactions is set up. The three reactions correspond to the
reference DNA (C57BL6), BALBc, and no template. This
group is duplicated on the plate, and a similar plate was repeated
three times to achieve statistical significance. The reactions were
formulated by using Applied Biosystems SYBRGreen PCR core
reagents kit, and the PCR was performed on an ABI Prism 7700
sequence detection system.
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